Source study found
Story checked
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People (opens in a new tab)
scitechdaily.com · 2026-10-08
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Long-Acting HIV Shots Could Solve a Major Treatment Challenge for Young People
scitechdaily.com · 2026-10-08
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 8Not checkedA major African randomized trial suggests that changing how HIV treatment is delivered could significantly improve viral suppression in adolescents.View evidenceHide evidence
As statedcould significantly improve
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 8Not checkedYoung people with HIV were more likely to keep the virus suppressed when they received treatment by injection every eight weeks instead of taking a pill every day.View evidenceHide evidence
As statedevery eight weeks instead of taking a pill every day
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 8Not checkedAfter 96 weeks, confirmed viral rebound occurred in two adolescents (1%) receiving long-acting injectable therapy, compared with 15 (6%) taking daily tablets.View evidenceHide evidence
As statedtwo adolescents (1%) vs 15 (6%)
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 8Not checkedThe LATA trial included 476 adolescents aged 12 to 19 at five clinics in Kenya, South Africa, Uganda and Zimbabwe, and participants were randomly assigned to standard daily tablet treatment or injections of cabotegravir and rilpivirine every eight weeks.View evidenceHide evidence
As stated476 adolescents; five clinics; every eight weeks
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 5 of 8Not checkedNearly all (94%) adolescents in the long-acting injectable group said injections every eight weeks were much easier than taking medication every day.View evidenceHide evidence
As stated94%
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 6 of 8Not checkedThe article says the findings, published in The Lancet, go beyond earlier adult trials because in this adolescent trial the injections produced better viral suppression than standard oral treatment.View evidenceHide evidence
As statedbetter viral suppression
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 7 of 8Not checkedThe article says access remains a major barrier because the medicines are under patent, cost more than tablets, require refrigeration, and must be administered by trained nursing staff every eight weeks.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 8 of 8Not checkedThe article says the World Health Organization currently recommends long-acting injections as an alternative option for adults and adolescents whose virus is successfully suppressed on daily tablets and who do not have active hepatitis B.View evidenceHide evidence
As statedalternative option
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
The Lancet · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, PubMed, Europe PMC · 37 candidate papers
Switch to injectable cabotegravir–rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial
The Lancet · 2026 · Crossref
Efficacy and safety of short-cycle, dolutegravir-based antiretroviral therapy in adolescents living with HIV (BREATHER Plus): a multicentre, open-label, randomised, parallel, two-arm, non-inferiority trial.
The Lancet. HIV · 2026 · PubMed
Unmet and Overlooked Needs of Pregnant Adolescents and Young Mothers in Zimbabwe: The Mixed-Methods “Kids With Kids” Study
Journal of Adolescent Health · 2026 · Crossref
Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.
The Lancet. HIV · 2026 · PubMed, Europe PMC, Crossref
Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial
Pediatric Infectious Disease Journal · 2026 · Crossref
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
The Lancet. Child & Adolescent Health · 2026 · PubMed
And 31 more candidates considered.